Protalix BioTherapeutics (PLX) Net Income towards Common Stockholders (2010 - 2026)

Protalix BioTherapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $18.4 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 608.1% year-over-year to $18.4 million in Q1 2026; TTM through Mar 2026 was $17.6 million, a 108.29% increase from a year earlier, with the FY2025 full-year figure at -$4.7 million, down 162.62% from the prior year.
• Net Income towards Common Stockholders rose to $18.4 million in Q1 2026 per PLX's latest filing, from -$3.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $18.4 million in Q1 2026 and bottomed at -$20.1 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$2.3 million (2022), against an average of -$107117.6.
• Across the five-year window, Net Income towards Common Stockholders slumped 526.92% in 2023 and surged 608.1% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$3.2 million in 2022, then slumped by 526.92% to -$20.1 million in 2023, then soared by 153.7% to $10.8 million in 2024, then slumped by 133.17% to -$3.6 million in 2025, then jumped by 613.06% to $18.4 million in 2026.
• Per Business Quant, the three latest PLX Net Income towards Common Stockholders figures stand at $18.4 million (Q1 2026), -$3.6 million (Q4 2025), and $2.4 million (Q3 2025).